Navigation Links
Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Date:11/1/2007

WASHINGTON, Nov. 1 /PRNewswire-USNewswire/ -- Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade. Recent analyses suggest that this trend may be attributed to new types of drugs and aggressive therapeutic interventions such as stem cell transplantation, according to the results of two studies prepublished online in Blood, the official journal of the American Society of Hematology.

Multiple myeloma (MM) is a neoplasm of plasma cells, a type of cell that resides in the bone marrow and produces antibody proteins. Survival rates for MM have traditionally been grim, with most patients dying within two to three years after diagnosis. However, within the last decade, a group of new therapies has been developed and approved for use in MM patients, including thalidomide (Thalidomid(R)), lenalidomide (Revlimid(R)), and bortezomib (Velcade(R)). Used alone or paired with traditional chemotherapy, these drugs have been shown to be highly effective in recently diagnosed and relapsed MM patients. Also, over the past decade high-dose chemotherapy and peripheral blood stem cell transplantation has been increasingly used for treatment of MM, especially in younger patients. Two recent studies analyzed outcomes in large populations of MM patients, comparing results with regard to diagnosis date, age, and gender.

Recent Major Improvement in Long-Term Survival of Younger Patients with Multiple Myeloma

In one study, a research team from the German Cancer Research Center and Weill Cornell Medical Center in New York analyzed trends in five- and 10-year survival of MM patients in the U.S. to understand how new therapies and innovative approaches have translated into better survival for patients. In this large epidemiologic study, 26,523 patients diagnosed with MM in the U.S. were studied from the 1990-1992 to 2002-2004 SEER (Surveillance, Epidemiology, and End
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ... has resigned from the Company,s Board of Directors in ... a co-founder of Impax in 1995 and served as ... 2006 until April 2014. Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO ... President and Chief Executive Officer stated, "We wish to ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
Breaking Medicine Technology:Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to ... yet there is a large gap between the unmet health priorities in the ... health outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone ...
(Date:7/6/2015)... ... 06, 2015 , ... Olive Fertility Centre is proud to announce that Olive ... on behalf of the department of Family Practice. , “This award is a real ... in. The technology is changing so rapidly and we are also developing new models ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... ... disease prevention in southern California, has partnered with Woodbridge Walk-In Urgent Care to ... cancer, stroke and other serious medical conditions. Screenings are affordable and accurate and ...
(Date:7/6/2015)... ... ... Health care systems and genomics projects have generated massive patient data sets ... this “Big Data” to improve health and cut costs is now on the horizon, ... Health System in New York City. Physicians will have these new capabilities within two ...
(Date:7/6/2015)... ... July 06, 2015 , ... In a split second, breaking a bone can ... of having a fracture through the bone health screenings conducted by American Bone Health ... participating because our residents need this information to remain independent and strong for many ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2
... SAN DIEGO, Aug. 31 Arena Pharmaceuticals,Inc. (Nasdaq: ... to,present at the NewsMakers in the Biotech Industry Conference ... a.m. Pacific Time) at the,Millennium Broadway Hotel in New ... is scheduled to provide a corporate overview,of the company ...
... chemical agent that may be a, if not the, ... lung, a severe occupational lung disease first noted in ... microwaveable popcorn. , The research, which examined ... produced diacetyl (a key component of butter flavoring), was ...
... to remain Chairman of the Board, SAN DIEGO, ... today that its board of directors has unanimously approved ... January,1, 2008, Kieran T. Gallahue will be promoted to ... Mr. Gallahue, 44, will succeed Dr. Peter,C. Farrell, 65. ...
... members of SEIU UHW-West and 121RN, their, first ... hospital, BURBANK, Calif., Aug. 30 Caregivers at ... United Healthcare Workers -,West (UHW) and SEIU 121RN, reached ... Medical Center. The contract, which expires,Sept. 30, 2011, grants ...
... Hospital ... Market-Competitive Rates, SAN DIEGO, Aug. 30 Today ... large insurance company,that is attempting to force the newly-independent hospital to ... and aggressive negotiating tactics are,designed to break the backs of independent ...
... Treated, ASHEVILLE, N.C., Aug. 30 Evangelist Billy ... has returned to his,mountain home in nearby Montreat, NC, ... the 20-minute drive home without incident. Mr. Graham ... NC,early on Saturday, August 18 for treatment of intestinal ...
Cached Medicine News:Health News:Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Health News:Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Health News:Chemical culprit in 'popcorn worker's lung' identified 2Health News:ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008. 2Health News:Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract 2Health News:Alvarado Hospital Files Countersuit Against Blue Shield 2Health News:Alvarado Hospital Files Countersuit Against Blue Shield 3Health News:Billy Graham Home After Hospitalization: 2
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
... Spectrophotometer is truly a ... instrumentation. The latest electro-optical ... a radically new design, ... performance unprecedented in a ...
... Quebec Colony Counter allows the user to quickly ... models allows for digital counting or manual counting. ... standard lens increasing magnification to 3.0X. The adjustable ... be raised or lowered. The lens also rotates ...
The Accucount 1000 is designed to automatically count macroscopic objects in a field displaying totals on a highly visible digital readout....
Medicine Products: